{"organizations": [], "uuid": "ede50f22a7aea45f7df7900de91f42e51e2b49dd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180228.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-respiratorius-presents-positive-re/brief-respiratorius-presents-positive-results-from-clinical-studies-of-val001-idUSFWN1QI0EH", "country": "US", "domain_rank": 408, "title": "BRIEF-Respiratorius Presents Positive Results From Clinical Studies Of VAL001", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-02-28T15:30:00.000+02:00", "replies_count": 0, "uuid": "ede50f22a7aea45f7df7900de91f42e51e2b49dd"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-respiratorius-presents-positive-re/brief-respiratorius-presents-positive-results-from-clinical-studies-of-val001-idUSFWN1QI0EH", "ord_in_thread": 0, "title": "BRIEF-Respiratorius Presents Positive Results From Clinical Studies Of VAL001", "locations": [], "entities": {"persons": [{"name": "respiratorius", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "rituximab", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 28 (Reuters) - RESPIRATORIUS AB (PUBL):\n* RESPIRATORIUS PRESENTS POSITIVE RESULTS FROM CLINICAL STUDIES OF VAL001\n* ‍PUBLISHED SCIENTIFIC RESULTS FROM PHASE I STUDY SHOW A POTENTIAL SYNERGISTIC EFFECT WITH RITUXIMAB AS VAL001 INCREASES LEVELS OF SURFACE PROTEIN CD20​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-28T15:30:00.000+02:00", "crawled": "2018-03-01T21:10:15.001+02:00", "highlightTitle": ""}